Company profile
UK company 12543677, incorporated on 1 April 2020.
Home - Purespring Therapeutics
Purespring Therapeutics Limited is a UK company with status Active founded in 2020 based in London.
Company number 12543677
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AD03 | Transaction MzUzNjcwNTc3OGFkaXF6a2N4
Published 03 Aug 2026 14:55
AD02 | Transaction MzUzNTc3NzgwNGFkaXF6a2N4
Published 30 Jul 2026 09:50
SH10 | Transaction MzUyMDI2MDc5M2FkaXF6a2N4 | Paper/PDF filed
Published 27 May 2026 23:11
SH08 | Transaction MzUyMDI2MDc5MWFkaXF6a2N4 | Paper/PDF filed
Published 27 May 2026 22:56
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Purespring Therapeutics develops gene therapies for kidney related diseases.
Purespring will develop gene therapies directly targeting the glomerulus in the kidney, which could see treatment progress from lab to patients in three or four years. The company will also have access to an in-vivo functional screening platform, FunSel, to screen for cell-specific protective factors delivered via gene therapy, that could have applications across several kidney diseases.
6 patents filed
The University of Bristol has secured a £45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company.
